- 期刊
- OpenAccess
Review of Tolvaptan in the Treatment of Hyponatremia
並列摘要
Hyponatremia is a very common electrolyte disorder and is a significant independent predictor of medical prognosis and costs. Tolvaptan is a vasopressin receptor antagonist developed for the treatment of hyponatremia. It has its principal application in the treatment of euvolemic and hypervolemic hyponatremia. Its major role is in the treatment of heart failure (HF), cirrhosis and the syndrome of inappropriate antidiuretic hormone secretion (SIADH). While at present tolvaptan has not demonstrated long term survival benefit with its use, it clearly has proven short term efficacy in the management of hyponatremia by demonstrating improvement in serum sodium levels at an acceptable rate without evidence of over-correction.
延伸閱讀
- 藍英明、陳稼洺、林正德（2010）。Treatment of Dysosmia: A Case Report。台灣中醫臨床醫學雜誌，16(2)，110-115。https://doi.org/10.6968/TJCCM.201006.0110
- 陳烱暉（1969）。Hyponatremia in Children。Acta Paediatrica Sinica，10(4)，141-151。https://www.airitilibrary.com/Article/Detail?DocID=00016578-196912-10-4-141-151-a
- 曾敏峯、許育瑞（2017）。Etiology and Management of Hypocalcemia: A Brief Review。腎臟與透析，29(1)，32-35。https://doi.org/10.6340/KD.2017.29(1).06
- Romanovsky, A., Bagshaw, S., & Rosner, M. H. (2011). Hyponatremia and Congestive Heart Failure: A Marker of Increased Mortality and a Target for Therapy. International Journal of Nephrology, 2011(), 628-634. https://doi.org/10.4061/2011/732746
- Stathopoulos, G. P., & Boulikas, T. (2012). Lipoplatin Formulation Review Article. Journal of Drug Delivery, 2012(), 208-217. https://doi.org/10.1155/2012/581363